Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Harvard Medical School, Boston, MA, USA.
Nature. 2022 May;605(7910):532-538. doi: 10.1038/s41586-022-04682-5. Epub 2022 May 4.
Within the tumour microenvironment, CD4 T cells can promote or suppress antitumour responses through the recognition of antigens presented by human leukocyte antigen (HLA) class II molecules, but how cancers co-opt these physiologic processes to achieve immune evasion remains incompletely understood. Here we performed in-depth analysis of the phenotype and tumour specificity of CD4 T cells infiltrating human melanoma specimens, finding that exhausted cytotoxic CD4 T cells could be directly induced by melanoma cells through recognition of HLA class II-restricted neoantigens, and also HLA class I-restricted tumour-associated antigens. CD4 T regulatory (T) cells could be indirectly elicited through presentation of tumour antigens via antigen-presenting cells. Notably, numerous tumour-reactive CD4 T clones were stimulated directly by HLA class II-positive melanoma and demonstrated specificity for melanoma neoantigens. This phenomenon was observed in the presence of an extremely high tumour neoantigen load, which we confirmed to be associated with HLA class II positivity through the analysis of 116 melanoma specimens. Our data reveal the landscape of infiltrating CD4 T cells in melanoma and point to the presentation of HLA class II-restricted neoantigens and direct engagement of immunosuppressive CD4 T cells as a mechanism of immune evasion that is favoured in HLA class II-positive melanoma.
在肿瘤微环境中,CD4 T 细胞可以通过识别人类白细胞抗原(HLA)II 类分子呈递的抗原来促进或抑制抗肿瘤反应,但癌症如何利用这些生理过程来实现免疫逃逸仍不完全清楚。在这里,我们对浸润人类黑色素瘤标本的 CD4 T 细胞的表型和肿瘤特异性进行了深入分析,发现耗尽的细胞毒性 CD4 T 细胞可以通过识别 HLA 类 II 受限的新抗原,以及 HLA 类 I 受限的肿瘤相关抗原,被黑色素瘤细胞直接诱导。CD4 调节性(T)细胞可以通过抗原呈递细胞呈递肿瘤抗原而间接产生。值得注意的是,许多肿瘤反应性 CD4 T 克隆被 HLA 类 II 阳性的黑色素瘤直接刺激,并对黑色素瘤新抗原具有特异性。在存在极高的肿瘤新抗原负荷的情况下观察到这种现象,我们通过对 116 个黑色素瘤标本的分析证实了这种现象与 HLA 类 II 阳性有关。我们的数据揭示了黑色素瘤中浸润性 CD4 T 细胞的景观,并指出 HLA 类 II 受限的新抗原的呈递和免疫抑制性 CD4 T 细胞的直接参与是 HLA 类 II 阳性黑色素瘤中有利于免疫逃逸的机制。